November 2, 2011Open Access

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Key Points

Key points are not available for this paper at this time.

Abstract

The iCasp9 cell-suicide system may increase the safety of cellular therapies and expand their clinical applications. (Funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute; ClinicalTrials.gov number, NCT00710892.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Stasi et al. (Wed,) studied this question.

synapsesocial.com/papers/69dcc6cc5f9113867535919d https://doi.org/https://doi.org/10.1056/nejmoa1106152

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients1996 · 575 citations
2Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’2001 · 839 citations
3Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial2010 · 381 citations
4Graft-versus-leukemia effects of transplantation and donor lymphocytes2008 · 577 citations
5Prospects for Stem Cell-Based Therapy2008 · 301 citations

Bookmark

View Full Paper